- Home
- ZLAB
ZLAB
Zai Lab Limited
as 05-07-2025 4:00pm EST
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | 3.5B | IPO Year: | 2017 |
| Target Price: | $47.37 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.65 - $39.77 | Next Earning Date: | 05-08-2025 |
| Revenue: | $398,988,000 | Revenue Growth: | 49.59% |
| Revenue Growth (this year): | 44.43% | Revenue Growth (next year): | 48.68% |
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Du Ying | ZLAB | Chairperson & CEO | Apr 3 '25 | Sell | $33.11 | 2,945 | $97,503.06 | 479,851 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Apr 3 '25 | Sell | $33.11 | 924 | $30,591.79 | 27,047 | |
| Smiley Joshua L | ZLAB | See Remarks | Apr 3 '25 | Sell | $33.11 | 3,354 | $111,044.23 | 67,345 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Apr 3 '25 | Sell | $33.11 | 1,874 | $62,044.39 | 30,375 | |
| Amado Rafael | ZLAB | See Remarks | Apr 3 '25 | Sell | $33.11 | 3,029 | $100,284.13 | 45,178 | |
| Du Ying | ZLAB | Chairperson & CEO | Apr 1 '25 | Sell | $35.89 | 5,808 | $208,472.35 | 479,851 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Apr 1 '25 | Sell | $35.89 | 5,280 | $189,520.32 | 27,047 | |
| Smiley Joshua L | ZLAB | See Remarks | Apr 1 '25 | Sell | $35.89 | 11,740 | $421,395.56 | 67,345 | |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Apr 1 '25 | Sell | $35.89 | 4,369 | $156,820.89 | 30,375 | |
| Amado Rafael | ZLAB | See Remarks | Apr 1 '25 | Sell | $35.89 | 7,541 | $270,676.65 | 45,178 |
Latest Zai Lab Limited News
ZLAB Breaking Stock News: Dive into ZLAB Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Zai Lab Limited (ZLAB): Among the Best Breakout Stocks to Buy According to Analysts
Business Wire
13 days ago
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
Business Wire
15 days ago
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
MT Newswires
17 days ago
Zai Lab's Cancer Drug Application Accepted by Chinese Regulator
Business Wire
17 days ago
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
Zacks
23 days ago
All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy
Zacks
24 days ago
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?
Business Wire
24 days ago
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
Compare ZLAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.